(Q39012223)

8 September 2017

Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects (English)

1 reference

8 September 2017

1 reference

1 reference

1

Sharon E Frey

1 reference

8 September 2017

Mari Rose Aplasca-De Los Reyes

2

1 reference

8 September 2017

Humberto Reynales

3

1 reference

8 September 2017

Nancy Nazaire Bermal

4

1 reference

8 September 2017

Uwe Nicolay

5

1 reference

8 September 2017

Vas Narasimhan

6

1 reference

8 September 2017

Eduardo Forleo-Neto

7

1 reference

8 September 2017

Ashwani Kumar Arora

8

1 reference

8 September 2017

language of work or name

English

0 references

publication date

18 July 2014

1 reference

8 September 2017

1 reference

8 September 2017

32

1 reference

8 September 2017

39

1 reference

8 September 2017

5027-5034

1 reference

Antibody response to influenza vaccination in the elderly: a quantitative review

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

The history of MF59(®) adjuvant: a phoenix that arose from the ashes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

MF59 adjuvanted seasonal and pandemic influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Oil-in-water emulsion adjuvant with influenza vaccine in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Extremely low vaccine effectiveness against influenza H3N2 in the elderly during the 2012/2013 flu season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

2011-12 seasonal influenza vaccines effectiveness against confirmed A(H3N2) influenza hospitalisation: pooled analysis from a European network of hospitals. A pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Mapping the antigenic and genetic evolution of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Age distribution of influenza like illness cases during post-pandemic A(H3N2): comparison with the twelve previous seasons, in France.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Heterogeneity of influenza case definitions and implications for interpreting and comparing study results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.013

10.1016/J.VACCINE.2014.07.013

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference